Home - VHIO

The drug OMO-103, developed by Peptomyc, will be tested as a therapy for patients with advanced osteosarcoma

This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology...

Violeta Serra, Guillermo Villacampa, Judith Balmaña

The promise of RAD51 testing in tailoring treatment strategies in early breast cancer

Published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), results of a VHIO-led study...

First-line immunotherapy combination improves outcomes in patients with metastatic colorectal cancer versus chemotherapy

Led by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase...

This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology...

The drug OMO-103, developed by Peptomyc, will be tested as a therapy for patients with advanced osteosarcoma

Published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), results of a VHIO-led study...

The promise of RAD51 testing in tailoring treatment strategies in early breast cancer

Led by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase...

First-line immunotherapy combination improves outcomes in patients with metastatic colorectal cancer versus chemotherapy

Latest News

This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology...

16 January 2025

The drug OMO-103, developed by Peptomyc, will be tested as a therapy for patients with advanced osteosarcoma

This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology...

Published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), results of a VHIO-led study...

13 January 2025

The promise of RAD51 testing in tailoring treatment strategies in early breast cancer

Published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), results of a VHIO-led study...

Led by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase...

07 January 2025

First-line immunotherapy combination improves outcomes in patients with metastatic colorectal cancer versus chemotherapy

Led by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase...

Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the...

23 December 2024

Addition of PI3K inhibition could improve outcomes in patients with PIK3CA-mutated metastatic breast cancer

Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the...

VIEW MORE NEWS

PRINCIPAL RESEARCHERS

Cristina Saura

Breast Cancer & Melanoma Group

The main area of expertise of the Breast Cancer Group is clinical research focused on drug development and associated translational…

Elena Garralda

Early Clinical Drug Development Group

We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and…

Teresa Macarulla

Gastrointestinal and Endocrine Tumors Group

Our group continues to play an essential role in developing molecular therapies against GI malignancies. We make important contributions to…

Alena Gros

Tumor Immunology and Immunotherapy Group

Our group focuses on better understanding the naturally occurring T-cell response to cancer and establishing ways to exploit these antitumor…

Latest News

PRINCIPAL RESEARCHERS

Events